Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis

Reneo Pharmaceuticals logo

About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)

Advanced Chart

Key Stats

Today's Range
$1.68
$1.90
50-Day Range
$1.31
$1.82
52-Week Range
$0.98
$9.21
Volume
437,523 shs
Average Volume
250,384 shs
Market Capitalization
$60.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RPHM Stock News Headlines

Onkure Therapeutics Inc (OKUR)
A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
See More Headlines

RPHM Stock Analysis - Frequently Asked Questions

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its quarterly earnings data on Monday, March, 27th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.03.

Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reneo Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Invesco QQQ (QQQ), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
3/27/2023
Today
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RPHM
CIK
1637715
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$77.39 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-62.52%
Return on Assets
-56.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
57.86
Quick Ratio
57.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.66 per share
Price / Book
0.68

Miscellaneous

Outstanding Shares
33,430,000
Free Float
27,439,000
Market Cap
$60.84 million
Optionable
Optionable
Beta
0.21
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:RPHM) was last updated on 7/29/2025 by MarketBeat.com Staff
From Our Partners